Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02680743|
Recruitment Status : Completed
First Posted : February 11, 2016
Last Update Posted : October 12, 2018
Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of pediatric sensorineural hearing loss (SNHL) and an important cause of neurodevelopmental delay. Infants with cCMV can be symptomatic, asymptomatic, or asymptomatic except for hearing loss. Symptomatic infants may be more readily identified and quickly referred for intervention because they may present with classic common clinical findings, but the majority of infants (85-90%) with cCMV are asymptomatic at birth and do not have the classic clinical, laboratory, or radiologic findings and therefore often have delayed identification and intervention. Often, these otherwise asymptomatic infants with cCMV may have early congenital hearing loss and therefore fail the newborn hearing screen but because they are not specifically identified as having cCMV there is a delay in seeking further audiology exam and treatment of the CMV infection.
The overall objective of this proposed research is to investigate how testing newborns for congenital cytomegalovirus infection (cCMV) after a failed newborn hearing screens can improve early identification of cCMV infection and therefore reduce the delay in referral of the newborn to appropriate specialists for intervention.
Eligible participants will include newborns in the NBN or NICU who are less than 14 days of life who fail the standard hearing screening.
Interventions and Evaluations Saliva samples will be obtained from participating infants with a mouth swab according to an established protocol. The saliva will then be tested for CMV by qualitative polymerase chain reaction by ARUP Laboratories. Infants who test positive for CMV infection will then be referred for repeat audiology exam to confirm hearing loss and to Pediatric Infectious Diseases for evaluation and treatment if necessary. Parents or guardians of infants who test positive for cCMV will receive counseling on the importance of following up with these specialists. The primary outcomes measured will be cCMV prevalence data and time to referral and intervention.
Follow-up will be as clinically indicated and determined by the infant's primary care provider, pediatric infectious disease physician, and audiologist. It will not be determined by the study, referral to these services will be the study endpoint.
|Condition or disease||Intervention/treatment||Phase|
|Congenital CMV Infection||Other: Education of parents to pursue prompt hearing screening.||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit|
|Study Start Date :||March 2016|
|Actual Primary Completion Date :||May 2018|
|Actual Study Completion Date :||May 2018|
Experimental: Intervention Group
Patients who fail newborn hearing screen will be screened for CMV by saliva PCR. If positive they will be referred for early hearing screen follow-up and early intervention.
They will also receive a consult with PEdiatric Infectious Disease to evaluate need for treatment.
Intervention:Education of parents to pursue prompt hearing screening.
Other: Education of parents to pursue prompt hearing screening.
Parents of patients will be counseled on the risks of hearing loss with a positive screen.
- Feasibility of in hospital screening of well newborns who fail the hearing screen for cCMV [ Time Frame: One month ]We will evaluate the ability of this intervention to decrease the time to the first hearing screen.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02680743
|United States, Nebraska|
|Nebraska Medicine Bellevue|
|Bellevue, Nebraska, United States, 68123|
|Omaha, Nebraska, United States, 68198|
|Principal Investigator:||Ann Anderson Berry||UNMC|